Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 Pipeline Review, H2 2018
Summary
According to the recently published report 'Cell Division Cycle 7 Related Protein Kinase Pipeline Review, H2 2018'; Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 Cell division cycle 7related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.
The report 'Cell Division Cycle 7 Related Protein Kinase Pipeline Review, H2 2018' outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Pancreatic Cancer, Solid Tumor, Esophageal Cancer, Metastatic Colorectal Cancer, Ovarian Cancer, Squamous NonSmall Cell Lung Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Blood Cancer, Breast Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, NonSmall Cell Lung Cancer and Transitional Cell Cancer Urothelial Cell Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1
The report reviews Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase CDC7 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope